Carta Healthcare, whose software platform applies AI to structured and unstructured data to decrease the time and costs for data abstraction, has acquired Realyze Intelligence, which applies similar technology to oncology.
Founded in 2019, San Francisco-based Carta Healthcare said it applies both artificial intelligence and expert clinical data abstractors to serve a wide range of health systems nationwide, from standalone community hospitals to large academic medical centers. It lists Mass General Brigham, CommonSpirit and Grady as among its health system customers.
Realyze Intelligence was formed in 2020 as a portfolio company of UPMC Enterprises, the innovation, commercialization and venture capital arm of UPMC. Its software analyzes structured and unstructured data in electronic health records to identify ideal patients for clinical trials and other research studies. The company says its clinician-trained AI can assemble appropriate cohorts in seconds instead of the typical hours or days the process consumes when performed manually. Realyze Intelligence is utilized by cancer centers and is part of the Memorial Sloan Kettering Cancer Center Innovation Hub. The CancerX Accelerator Program also selected Realyze Intelligence as part of its inaugural program earlier this year.
Terms of the acquisition were not disclosed.
A Realyze Intelligence analysis found that by using the software, UPMC Hillman Cancer Center saw seven times more patients matched to trials and twice as many enrolled, compared to the same timeframe without using the software.
“We believe data is the single most important ingredient to improve healthcare,” said Brent Dover, CEO of Carta Healthcare, in a statement. “From clinical trials to clinical registries, clinicians face insurmountable amounts of data ripe with valuable information to improve care practices and patient outcomes. We are inspired by Realyze Intelligence’s shared ability to use clinician-trained AI and a human-in-the-loop approach to maximize insights from clinical data, for clinical trials and cancer registries.”
“Health systems and pharmaceutical companies invest billions annually to identify and enroll patients for clinical trials—a process that is not only costly but labor-intensive and time-consuming,” said Aaron Brauser, founder and CEO of Realyze Intelligence, in a statement. “High-quality, timely data is essential for accurately identifying eligible patients, yet much of it remains trapped in EHRs and other systems. We are excited to revolutionize clinical trial matching and reuse the data to enhance research, optimize care pathways and improve patient outcomes with Carta Healthcare.”
